BPC-157 and TB-500: why these two peptides are studied together

Two peptides with complementary proposed mechanisms — both currently Category 2, both pending the formal reclassification process.

TL;DR

• BPC-157 and TB-500 are often discussed together in tissue-repair contexts because their proposed mechanisms address different parts of the repair process: BPC-157 around angiogenesis and matrix-level signaling, TB-500 around actin regulation and cell migration.
• The combination is sometimes referred to as a “RECOVER” protocol concept. It is a research-driven hypothesis, not a validated clinical protocol.
• Both peptides are currently Category 2 and not available through Halftime Health. If the FDA reclassification process moves forward, the combined-use framing is one of the most-discussed scenarios.

What it is

The BPC-157 / TB-500 pairing is one of the most-discussed combinations in peptide-protocol contexts. The rationale, when stated carefully, is mechanistic complementarity: each peptide is proposed to influence a different part of the tissue-repair process, and the hypothesis is that combining them addresses repair more comprehensively than either alone.

How the proposed mechanisms differ

BPC-157’s proposed mechanisms center on angiogenesis (new blood vessel formation, supporting blood and oxygen delivery to healing tissue), nitric oxide signaling, growth factor upregulation, and matrix-level tissue repair effects observed in animal models (Sikiric et al., Current Pharmaceutical Design, 2018).

TB-500 (and full Thymosin Beta-4)‘s proposed mechanisms center on actin sequestration (regulating cellular shape change and migration), modulation of inflammatory signaling, promotion of cell migration into injury sites, and angiogenic effects in some tissue contexts (Crockford et al., Annals of the New York Academy of Sciences, 2010).

The complementarity argument is straightforward: BPC-157 addresses angiogenic and matrix-level support, TB-500 addresses cellular migration and inflammation modulation. Together — under the hypothesis — they cover more of the repair process than either alone.

The RECOVER protocol concept

In peptide-protocol discussions, this combination is sometimes referred to as a “RECOVER” protocol — a label that captures the tissue-repair-focused use case. The concept is research-driven and theoretical rather than a validated clinical protocol. Robust randomized human trials of the combination for tissue-repair indications are not available in the published literature.

Why both are Category 2

The 2023 PCAC vote placed both BPC-157 and TB-500 in Category 2, primarily because the human safety and efficacy data for each — at the standard required for 503A compounding eligibility — was not yet available. The February 2026 HHS announcement proposed returning both peptides to Category 1, along with five others. As of April 2026, the formal Federal Register notice required to make that change effective had not been published.

Who asks about it

People come to this topic when they have heard the BPC-157 + TB-500 combination described in tissue-repair contexts and want to understand the rationale. The honest summary is that the mechanistic complementarity argument is reasonable, the underlying preclinical research is real, and the combination is currently theoretical because both peptides are unavailable through licensed compounding pharmacies.

What to know before considering it

Neither BPC-157 nor TB-500 is available through Halftime Health, and neither can legally be obtained through a U.S. licensed compounding pharmacy as of April 2026. People with persistent tissue-injury complaints should be evaluated by an appropriate clinician — orthopedist, sports medicine physician, or primary care — using established diagnostic and treatment pathways.

The Halftime POV

If the formal reclassification process moves forward, BPC-157 and TB-500 are two of the peptides that would most plausibly be combined in a recovery-focused protocol. We are watching the regulatory process closely. Until and unless the formal Federal Register notice is published, the combination remains a research hypothesis rather than a clinical reality, and Halftime Health does not offer it.

Related reading:

• BPC-157 for tissue repair and recovery: the evidence
• TB-500 for tissue repair: what the research shows
• BPC-157 and the FDA: Category 2 status and what comes next
• TB-500 regulatory status: Category 2 and the path forward

FAQ

Q: Why are BPC-157 and TB-500 often discussed together? A: Their proposed mechanisms are complementary. BPC-157 has been investigated for promoting angiogenesis and supporting mucosal and matrix-level tissue repair. TB-500 has been investigated for actin regulation, cell migration, and inflammation modulation. The hypothesis behind pairing them is that the two mechanisms address different stages of the repair process. Both are Category 2 peptides as of April 2026 and not available through Halftime Health.

Q: What is the RECOVER protocol concept? A: RECOVER is a framing used in peptide-protocol discussions to describe the combination of BPC-157 and TB-500 in tissue-repair contexts. It is a research-driven concept rather than a validated clinical protocol. Both peptides are currently Category 2, so the framing is theoretical. If the FDA reclassification process moves forward, a combined approach is one of the use cases that would be evaluated.

Q: Are BPC-157 and TB-500 available through Halftime Health? A: No. Both BPC-157 and TB-500 are Category 2 peptides as of April 2026 and cannot legally be prepared by 503A compounding pharmacies. The February 2026 HHS announcement proposed returning both to Category 1, but the formal FDA Federal Register notice required to make that change effective has not been published. Halftime Health does not currently offer either peptide.

Disclaimer

As of April 2026, both BPC-157 and TB-500 are classified by the FDA as Category 2 peptides and are not available through licensed 503A compounding pharmacies. A February 2026 HHS announcement proposed returning both to Category 1 pending formal FDA Federal Register notice. Halftime Health does not currently offer BPC-157 or TB-500. This article is educational only and is not medical advice.

Get updates

Halftime Health is launching soon. We’ll share what we learn along the way — the research, the regulations, the real-world trade-offs. Join the waitlist and we’ll email you when we’re live.

Sources

• Sikiric P, et al. Stable Gastric Pentadecapeptide BPC 157: Novel Therapy in Gastrointestinal Tract. Current Pharmaceutical Design, 2018.
• Crockford D, et al. Thymosin β4: structure, function, and biological properties. Annals of the New York Academy of Sciences, 2010.

This article discusses compounds that are currently under FDA Category 2 review (see our FDA categorization explainer). These compounds are not currently part of Halftime Health’s published protocol catalog. This article is provided for educational purposes only and does not constitute medical advice or an offer to sell.